SCHEMBL6158314

SCHEMBL6158314

CS(=O)(=O)OC1CC(=O)N(Cc2ccc(Oc3ccc(O)cc3)cc2)C1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.41
CYP2C19 P33261 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
KMT2A Q03164 1/20 0.40
ALDH1A1 P00352 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAPK1 P28482 2/20 0.38
ALOX15 P16050 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
HTT P42858 1/20 0.38
LMNA P02545 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
MMP2 P08253 2/20 0.36
MMP1 P03956 1/20 0.36
MMP3 P08254 1/20 0.36
MMP9 P14780 1/20 0.36
MMP13 P45452 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6158905 0.89 HPGD (0.44) CYP3A4CYP2C19SMN1; SMN2TDP1MMP2
SCHEMBL6160102 0.89 CYP3A4 (0.48) CYP3A4CYP2C19SMN1; SMN2KMT2AALDH1A1
SCHEMBL6160206 0.89 HPGD (0.44) CYP3A4CYP2C19SMN1; SMN2TDP1MMP2
SCHEMBL6162338 0.89 KMT2A (0.47) CYP3A4CYP2C19SMN1; SMN2KMT2AALDH1A1
SCHEMBL6161999 0.89 SMN1; SMN2 (0.49) CYP3A4CYP2C19SMN1; SMN2KMT2AALDH1A1
SCHEMBL6166461 0.88 HTT (0.48) CYP3A4CYP2C19SMN1; SMN2KMT2AALDH1A1
SCHEMBL6157027 0.87 ALDH1A1 (0.42) CYP3A4CYP2C19SMN1; SMN2KMT2AALDH1A1
SCHEMBL6158804 0.83 TDP1 (0.47) CYP3A4CYP2C19SMN1; SMN2KMT2AALDH1A1
SCHEMBL6160230 0.82 GRM2 (0.55) SMN1; SMN2KMT2AALDH1A1HRH3LMNA
SCHEMBL6160405 0.81 GRM2 (0.50) SMN1; SMN2KMT2AALDH1A1HRH3TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6953789-B2 Thiol compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-10-11 US disclosed
US-20040157894-A1 Thiol compounds, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-08-12 US disclosed
US-6699881-B2 MATRIX METALLOPROTEASE INHIBITORS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-03-02 US disclosed
US-20030078253-A1 Thiol compounds, their production and use TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) 2003-04-24 US disclosed
US-6420415-B1 Thiol compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-07-16 US disclosed
EP-1132379-A1 NOVEL THIOL DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF Takeda Chemical Industries, Ltd. (JP) 2001-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078253-A1 Thiol compounds, their production and use TST, QSOX1, SULT1E1 CYP3A4 274/4885CYP2C19 951/4885SMN1; SMN2 3819/4885
US-20040157894-A1 Thiol compounds, their production and use TST, SULT1E1, QSOX1 CYP3A4 195/4885CYP2C19 822/4885SMN1; SMN2 3509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.